within Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA07_AbiciparPegol;

model AbiciparPegol
  extends Pharmacolibrary.Drugs.ATC.S.S01LA07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01LA07</td></tr><td>route:</td><td>intravitreal</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Abicipar pegol is a designed ankyrin repeat protein (DARPin) that acts as a vascular endothelial growth factor A (VEGF-A) inhibitor. It was developed for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema by intravitreal injection. The drug showed prolonged intraocular half-life, allowing reduced injection frequency compared with existing anti-VEGF therapies. Despite positive efficacy results, abicipar pegol was not approved for clinical use due to safety concerns related to intraocular inflammation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adults with neovascular AMD following single-dose intravitreal administration.</p><h4>References</h4><ol><li><p>Ferro Desideri, L, et al., &amp; Nicolò, M (2020). Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration. <i>Expert opinion on investigational drugs</i> 29(7) 651–658. DOI:<a href=&quot;https://doi.org/10.1080/13543784.2020.1772754&quot;>10.1080/13543784.2020.1772754</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32479126/&quot;>https://pubmed.ncbi.nlm.nih.gov/32479126</a></p></li><li><p>Edington, M, et al., &amp; Chong, NV (2017). Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. <i>Expert opinion on drug metabolism &amp; toxicology</i> 13(12) 1217–1224. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2017.1404987&quot;>10.1080/17425255.2017.1404987</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29134820/&quot;>https://pubmed.ncbi.nlm.nih.gov/29134820</a></p></li><li><p>Luu, KT, et al., &amp; Attar, M (2020). A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition. <i>The Journal of pharmacology and experimental therapeutics</i> 373(2) 184–192. DOI:<a href=&quot;https://doi.org/10.1124/jpet.119.263178&quot;>10.1124/jpet.119.263178</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32098861/&quot;>https://pubmed.ncbi.nlm.nih.gov/32098861</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AbiciparPegol;
